RemeGen Executive and Leadership Team

Jianmin Fang, the Chief Executive Officer and CSO at RemeGen, directs the overarching scientific vision and drug discovery strategy. Overseeing the development of complex biologics like Telitacicept, Fang ensures the research pipeline maintains high clinical standards. This leadership role involves bridging the gap between laboratory innovation and commercial viability for autoimmune therapies. By managing the scientific roadmap, Jianmin Fang directly impacts the company's ability to address unmet medical needs in the global oncology and immunology markets. Fang coordinates with the board to prioritize high-potential assets, ensuring the biopharmaceutical portfolio remains competitive. Through the integration of advanced protein engineering, the Chief Executive Officer and CSO drives the technical evolution of the entire product suite. This strategic focus secures the long-term scientific authority of the organization while fostering a culture of continuous discovery and clinical excellence across all research departments.

Jian Lin, the Executive Director & Chief Executive Officer at RemeGen, manages corporate governance and the execution of long-term business objectives. Overseeing the expansion of the company's market presence, Lin ensures alignment between internal resources and external growth targets. This leadership role involves navigating complex regulatory landscapes to facilitate the global distribution of antibody-drug conjugates. By optimizing organizational structure, Jian Lin directly impacts the efficiency of the biopharmaceutical operations. Lin maintains strong relationships with investors and stakeholders to support the capital requirements of the research pipeline. Through the implementation of robust management frameworks, the Executive Director & Chief Executive Officer drives the strategic scaling of the business. This focus on operational discipline ensures that the company remains a leader in the pharmaceutical sector while delivering consistent value to patients and shareholders across diverse international markets.

Shaojing Tong, the Chief Financial Officer at RemeGen, directs all fiscal planning, capital allocation, and financial reporting activities. Overseeing the budgetary requirements for extensive research and development programs, Tong ensures the company maintains the liquidity necessary for sustained innovation. This leadership role involves managing investor relations and providing transparent financial oversight to the board. By implementing rigorous cost-control measures, Shaojing Tong directly impacts the financial health of the organization. Tong evaluates the economic feasibility of new drug candidates, ensuring that capital flows toward the most promising therapeutic assets. Through the management of global financial operations, the Chief Financial Officer drives the fiscal stability required to support the company's ambitious growth trajectory. This strategic financial management allows the organization to navigate the high-cost environment of biopharmaceutical manufacturing while securing the resources needed for long-term success in the competitive global healthcare market.

Kaisheng Huang, the Chief Operating Officer & Chief Quality Officer at RemeGen, directs the manufacturing processes and quality assurance protocols across all production facilities. Overseeing the supply chain and operational logistics, Huang ensures that every product meets the highest international safety and efficacy standards. This leadership role involves optimizing production workflows to increase output while maintaining strict regulatory compliance. By enforcing rigorous quality control measures, Kaisheng Huang directly impacts the reliability and consistency of the company's drug supply. Huang manages the integration of advanced manufacturing technologies to support the scaling of the product pipeline. Through the oversight of operational efficiency, the Chief Operating Officer & Chief Quality Officer drives the internal capabilities required to meet global demand. This commitment to operational excellence ensures that the organization maintains its reputation for quality while supporting the rapid delivery of life-saving medications to patients worldwide.

Michael Shi, the Chief Marketing Officer at RemeGen, directs the commercialization strategy and market positioning for the company's flagship products. Overseeing the launch of innovative therapies like Disitamab Vedotin, Shi ensures that medical professionals and patients understand the clinical benefits of these advanced treatments. This leadership role involves analyzing market trends to identify growth opportunities within the autoimmune and oncology sectors. By crafting targeted communication campaigns, Michael Shi directly impacts the adoption rates of the company's drug portfolio. Shi coordinates with regional sales teams to ensure effective market penetration across diverse geographic territories. Through the development of strategic partnerships, the Chief Marketing Officer drives the brand awareness necessary to establish the company as a premier provider of specialized medicine. This focus on commercial excellence ensures that the organization effectively translates scientific breakthroughs into tangible market success and improved patient outcomes on a global scale.